The ATACtrial: The vanguard trial for use of aromatase inhibitors in early breast cancer

Expert Review of Anticancer Therapy

Volumn 7, Issue 8, 2007, Pages 1089-1094

  Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adjuvant treatment; Anastrozole; Aromatase; Breast cancer; Hormone treatment; Inhibitor; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTHROPATHY; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARPAL TUNNEL SYNDROME; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLLES FRACTURE; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPAREUNIA; EARLY CANCER; ENDOMETRIUM CANCER; FATIGUE; FOLLOW UP; FRACTURE; GYNECOLOGIC DISEASE; HIP FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIBIDO DISORDER; MONOTHERAPY; MOOD DISORDER; MUSCLE CRAMP; MYCOSIS; NAIL DISEASE; NAUSEA AND VOMITING; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PARESTHESIA; POSTMENOPAUSE; RECURRENCE RISK; SIDE EFFECT; SPINE FRACTURE; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE INCONTINENCE; VAGINA BLEEDING; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; WRIST FRACTURE; XEROSTOMIA; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 34548433780     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.8.1089     Document Type: Article

References (9)

1. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359, 2131-2139 (2002).
2. ATAC Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - results of the ATAC trial efficacy and safety update analysis. Cancer 98, 1802-1810 (2003).
3. ATAC Trialists' Group. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 365, 60-62; correspondence 365, 1225-1226 (2005).
4. Dowsett M, Haynes BP. Hormonal effects of aromatase inhibitors focus on premenopausal effects and interaction with tamoxifen. J. Steriod Biochem. Mol. Biol. 86(3-5), 255-263 (2003).
5. ATAC Trialists Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 7(8) 633-643 (2006).
6. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
7. Eastell R, Hannon R, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on BMD and bone turnover markers 2-year results of the anastrozole, alone or in combination (ATAC) Trial. J. Bone Miner. Res 21(8), 1215-1223 (2006).
8. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of lifec of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast Cancer. Breast Cancer Res Treat. 100(3), 273-284 (2006).
9. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC Trial according to hormone receptor status an hypothesis-generating study. J. Clin. Oncol. 23(30), 7512-7517 (2005).